What are the recommended dosing regimens, contraindications, and monitoring parameters for artemether (including artemether‑lumefantrine) in the treatment of uncomplicated and severe malaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Artemether-Lumefantrine for Malaria Treatment

For uncomplicated P. falciparum malaria, artemether-lumefantrine (AL) is a first-line treatment administered as 4 tablets per dose (for patients ≥35 kg) given 6 times over 3 days: initial dose, second dose at 8 hours, then twice daily for 2 more days, with each dose taken with fatty food to ensure adequate absorption. 1

Dosing Regimens

Standard 3-Day (6-Dose) Regimen

Weight-based dosing for uncomplicated malaria:

  • 5 to <15 kg: 1 tablet per dose
  • 15 to <25 kg: 2 tablets per dose
  • 25 to <35 kg: 3 tablets per dose
  • ≥35 kg: 4 tablets per dose

Timing: Day 1: doses at 0 and 8 hours; Day 2: doses at 36 and 48 hours; Day 3: doses at 60 and 72 hours (total 24 tablets for adults over 72 hours) 1, 2

Extended 5-Day (10-Dose) Regimen - Updated CDC Guidance

Recent evidence shows increasing treatment failures with the standard 3-day regimen, particularly among travelers from Africa. From November 2022 through October 2025, CDC documented 47 P. falciparum treatment failures (40 following AL), with 85% being late recrudescences occurring 1-8 weeks post-treatment. Meta-analysis revealed pooled AL failure risk increased to 7% for data collected in 2018 or later versus 4% before 2018. 3

CDC now recommends an extended 5-day (10-dose) course for treating uncomplicated P. falciparum malaria in the United States, as this regimen achieves higher lumefantrine exposure and improved cure rates. 3

Critical Administration Requirements

AL MUST be taken with fatty food or drink - this is non-negotiable as lumefantrine absorption increases substantially with fat intake. Without food, treatment failure risk increases dramatically. 1, 2 For children unable to swallow tablets, crush and mix with 1-2 teaspoons of water immediately before administration. 2

Contraindications

Absolute contraindications:

  • Known hypersensitivity to artemether, lumefantrine, or excipients 2
  • Coadministration with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) - these reduce lumefantrine exposure by 68-89%, leading to treatment failure 2

Relative contraindications/use with extreme caution:

  • Known QT prolongation
  • Hypokalemia or hypomagnesemia
  • Concurrent use of other QT-prolonging drugs 1, 2

Do NOT use for:

  • Severe malaria (requires parenteral artesunate)
  • Malaria prophylaxis 2

Monitoring Parameters

Day 7 Lumefantrine Concentrations - Critical Threshold

Day 7 lumefantrine concentrations ≥200 ng/mL are associated with >98% cure rates (when baseline parasitemia <135,000/μL). Concentrations below this threshold significantly increase recrudescence risk (HR 1.59 per halving of concentration). 4

High-Risk Groups Requiring Closer Monitoring

Three populations face substantially increased treatment failure risk:

  1. Very young children (<3 years), especially malnourished:

    • Underweight-for-age children have 23% lower day 7 concentrations than adequately nourished children
    • 53% lower concentrations compared to adults
    • Consider the extended 5-day regimen 4

  2. High baseline parasitemia (>135,000/μL):

    • HR 1.87 for recrudescence per 10-fold increase in parasitemia
    • Extended regimen should be strongly considered 4

  3. Patients from areas with emerging artemisinin resistance or very low transmission intensity:

    • Highest recrudescence risk observed in these populations 4

Clinical Monitoring Schedule

  • Day 3: Check for parasite clearance - only 2/359 patients should have parasites remaining 5
  • Day 7: Measure lumefantrine concentrations if available, especially in high-risk groups
  • Day 28: Final assessment for treatment failure 1
  • Median parasite clearance time: 41.5 hours
  • Median fever clearance time: 36.8 hours 5

ECG Monitoring

QT prolongation is a significant concern. Avoid halofantrine within one month before or after AL treatment due to additive QT effects. Use caution with quinine and quinidine following AL treatment. 1, 2

Drug Interactions - Critical Considerations

CYP3A4 Interactions

Artemether and lumefantrine are metabolized by CYP3A4; lumefantrine also inhibits CYP2D6. 2

Strong CYP3A4 inducers (CONTRAINDICATED):

  • Rifampin reduces lumefantrine exposure by 68%, artemether by 89% - absolute contraindication 2

CYP3A4 inhibitors (use cautiously):

  • Ketoconazole increases artemether exposure 2.3-fold, lumefantrine 1.6-fold
  • Risk of QT prolongation with increased lumefantrine concentrations
  • Includes: macrolide antibiotics, imidazole antifungals, antiretrovirals 2

CYP2D6 substrates:

  • Lumefantrine significantly inhibits CYP2D6
  • Avoid concurrent use with CYP2D6 substrates that prolong QT (flecainide, imipramine, amitriptyline, clomipramine) 2

Antimalarial Interactions

Mefloquine: If used immediately before AL, causes 30% reduction in lumefantrine Cmax and 40% reduction in AUC. Encourage food consumption and monitor for decreased AL efficacy. 2

Quinine: No significant interaction, but monitor for additive QT prolongation 2

Hormonal Contraceptives

Effectiveness may be reduced - use additional non-hormonal birth control method during and for one cycle after AL treatment. 2

Pregnancy Considerations

AL is now recommended for all trimesters of pregnancy based on strong safety and efficacy evidence. 1, 6

  • Second and third trimesters: Preferred first-line treatment
  • First trimester: Treatment option when other options unavailable
  • WHO endorses ACTs including AL throughout pregnancy 6
  • Systematic review of 21 studies demonstrated safety and efficacy in pregnancy 6

Common Adverse Reactions

Adults (>30%): Headache, anorexia, dizziness, asthenia, arthralgia, myalgia 2

Children (>12%): Pyrexia, cough, vomiting, anorexia, headache 2

Most adverse events are mild-to-moderate and related to malaria itself rather than the drug. Treatment is generally well tolerated with few serious adverse events. 5

Critical Pitfalls to Avoid

  1. Unsupervised treatment: Results in 44% lower day 7 lumefantrine concentrations - directly observe therapy when possible 4

  2. Inadequate fat intake: Single most common cause of treatment failure - emphasize fatty meal/drink requirement

  3. Using standard 3-day regimen in high-risk groups: Consider extended 5-day regimen for very young/malnourished children, high parasitemia, or travelers from Africa 3, 4

  4. Concurrent rifampin use: Absolute contraindication due to massive reduction in drug exposure 2

  5. Ignoring QT risk factors: Screen for hypokalemia, hypomagnesemia, and QT-prolonging medications before initiating treatment

References

1
Guideline

how to manage adult patients with malaria in the non-endemic setting.

Clinical Microbiology and Infection, 2024

Related Questions

What are the strength and dosing regimen of the artemether‑lumefantrine (AL) combination, and how should malaria‑related headache and thrombocytopenia be managed?
How should artemether/lumefantrine be dosed for uncomplicated Plasmodium falciparum malaria in adults and children, and what are the guidelines for severe cases?
What are the indications, dosing regimen, and safety considerations for lumefantrine (artemether‑lumefantrine)?
Can artemether‑lumefantrine (Coartem) be used to treat uncomplicated Plasmodium falciparum malaria in a pregnant woman, and what are the recommended trimester‑specific safety considerations and dosing regimen?
Has the CDC changed its recommendation for artemether‑lumefantrine 80 mg/480 mg dosing in uncomplicated Plasmodium falciparum malaria to twice daily for five days instead of the standard three‑day regimen?
What is the next best treatment for persistent yeast balanitis after topical ketoconazole provided only symptomatic relief?
What is the appropriate management of esophageal perforation?
What is the appropriate dosing of buspirone (Buspar) and can it be used on an as-needed (PRN) basis?
In a 4‑month‑old infant with fever, bulging fontanelle, and an unsuccessful lumbar puncture, should I administer ampicillin plus cefotaxime or only ceftriaxone?
What causes glans pain when the foreskin is retracted in an uncircumcised male without any swelling or redness?
For a 61-year-old patient who has not had laboratory testing in over a year and is requesting weight‑loss medication such as Wegovy (semaglutide), what baseline labs and assessments are required before initiating therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.